In 2020, Lokki et al. described a successful case of postpartum HELLP syndrome treated with the complement C5 inhibitor Eculizumab (900 mg IV) after the failure to respond to the best supportive care (plasma exchange treatment on the first and second postpartum days, as well as hemodialysis three times over the course of the treatment. The gene discussed is C5; the disease is HELLP syndrome.